Skip Navigation



European Heart Journal Advance Access published online on April 15, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn164
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/10/1218    most recent
ehn164v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Palatini, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palatini, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Is there benefit of cardiac slowing drugs in the treatment of hypertensive patients with elevated heart rate?

Paolo Palatini*

Department of Clinical and Experimental Medicine, University of Padova, 35128 Padova, Italy

* Corresponding author. Tel: +39 049 8212278, Fax: +39 049 8754179, Email: palatini@unipd.it

This editorial refers to ‘Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapil STudy (INVEST)’ by R. Kolloch et al. doi:10.1093/eurheartj/ehn123

The first 150 words of the full text of this article appear below.

A large body of evidence indicates that resting heart rate is a strong independent predictor of cardiovascular morbidity and mortality.1–9 This association has been found to be present at all ages and in different clinical settings, irrespective of the presence of co-morbidities.1–9 The relationship was still present when subjects who died within the first years after baseline evaluation were excluded, thereby ruling out the possibility that the association between heart rate and mortality was due to some underlying chronic disease unrecognized at the time of baseline assessment.1,4,7 Overall, the results of ~50 longitudinal studies have been published on the relationship between heart rate and total and/or cardiovascular mortality, and the large majority have demonstrated that heart rate is a strong predictor of risk whereas no study has shown the reverse.8–11 The pathogenetic mechanisms accounting for the connection between high heart rate, atherosclerosis, and cardiovascular morbidity have been documented in many . . . [Full Text of this Article]

Conclusions


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST)
Rainer Kolloch, Udo F. Legler, Annette Champion, Rhonda M. Cooper-DeHoff, Eileen Handberg, Qian Zhou, and Carl J. Pepine
EHJ 2008 29: 1327-1334. [Abstract] [Full Text]